文献速递白血病

MicroRNA-497/195 在儿童急性淋巴细胞白血病中具抑瘤作用并与 CDKN2A/B 协同

MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2021-01-01

研究基于患者来源异种移植模型探索与移植速度和复发相关的 microRNA 表达,发现 miR-497/195 在移植慢、预后好的样本中高表达,在移植快、早期复发的样本中因表观遗传沉默而低表达;过表达可抑制白血病体内生长并延长受体生存,其机制涉及 CDK4 和 CCND3 介导的 G1/S 转换调控,且 miR-497/195 高表达联合 CDKN2A/B 完整序列与极好预后相关,而 CDKN2A/B 缺失联合低表达与无复发生存明显较差相关。

要点

  • miR-497/195 高表达见于移植慢、预后好的 BCP-ALL 样本,低表达与移植快和早期复发相关。
  • 过表达 miR-497/195 抑制体内白血病生长并延长受体生存,抑制则促进生长。
  • 机制涉及 CDK4 和 CCND3 介导的 G1/S 转换调控;miR-497/195 高表达联合 CDKN2A/B 完整与极好预后相关。

核心结论

  • miR-497/195 在儿童 BCP-ALL 中具抑瘤作用,其与 CDKN2A/B 的协同缺失构成新的预后因素并提示潜在治疗靶点。

研究设计与样本

  • 基于患者来源白血病细胞移植入 NOD/SCID 小鼠的异种移植模型,比较不同移植表型的 microRNA 表达,并在患者来源白血病细胞中进行过表达和抑制实验,另在独立患者样本系列中分析表达与预后关联。

主要发现

  • 移植慢且预后好的患者来源异种移植样本中 miR-497/195 高表达,移植快且早期复发的样本中表观遗传抑制和低表达。
  • 患者来源白血病细胞过表达 miR-497/195 抑制体内白血病生长并延长受体生存,抑制 miR-497/195 则增加白血病细胞生长。
  • miR-497/195 过表达下调关键细胞周期调控因子,CDK4 和 CCND3 介导的 G1/S 转换控制是抑制 BCP-ALL 进展的主要机制。
  • 独立患者样本中,miR-497/195 高表达联合 CDKN2A/B 完整序列与极好预后相关,CDKN2A/B 缺失联合 miR-497/195 低表达与无复发生存明显较差相关。

临床怎么用

  • 可将 miR-497/195 表达水平与 CDKN2A/B 缺失状态联合用于儿童 BCP-ALL 预后分层。
  • miR-497/195 及其下游 CDK4/CCND3 通路可能作为潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We previously identified an association of rapid engraftment of patient-derived leukemia cells transplanted into NOD/SCID mice with early relapse in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In a search for the cellular and molecular profiles associated with this phenotype, we investigated the expression of microRNAs (miRNAs) in different engraftment phenotypes and patient outcomes. We found high expression of miR-497 and miR-195 (hereafter miR-497/195) in patient-derived xenograft samples with slow engraftment derived from patients with favorable outcome. In contrast, epigenetic repression and low expression of these miRNAs was observed in rapidly engrafting samples associated with early relapse. Overexpression of miR-497/195 in patient-derived leukemia cells suppressed in vivo growth of leukemia and prolonged recipient survival. Conversely, inhibition of miR-497/195 led to increased leukemia cell growth. Key cell cycle regulators were downregulated upon miR-497/195 overexpression, and we identified cyclin-dependent kinase 4 (CDK4)- and cyclin-D3 (CCND3)-mediated control of G1/S transition as a principal mechanism for the suppression of BCP-ALL progression by miR-497/195. The critical role for miR-497/195-mediated cell cycle regulation was underscored by finding (in an additional independent series of patient samples) that high expression of miR-497/195 together with a full sequence for CDKN2A and CDKN2B (CDKN2A/B) was associated with excellent outcome, whereas deletion of CDKN2A/B together with low expression of miR-497/195 was associated with clearly inferior relapse-free survival. These findings point to the cooperative loss of cell cycle regulators as a new prognostic factor indicating possible therapeutic targets for pediatric BCP-ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Boldrin E, Gaffo E, Niedermayer A, et al. MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia. Blood. 2021. PMID: 34098582. doi:10.1182/blood.2020007591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。